RxDoctor Payments Data

John Bullock, MD

Family Medicine · Sumrall, MSNPI 1942217757

Payments from drug & device makers

$4,175in general payments, 2019–2025

Across 258 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$884
  • AbbVie$567
  • Pfizer$473
  • Lilly USA, LLC$255
  • GSK$186
  • Tris Pharma Inc$174
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,175100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,175 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$267,084
Medicare patients
565
Services billed
11,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$154,871
JardianceEmpagliflozin116$98,391
EliquisApixaban77$47,283
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$36,489
MounjaroTirzepatide17$33,885
LinzessLinaclotide32$30,042
RybelsusSemaglutide13$24,512
XareltoRivaroxaban43$23,429
Tresiba Flextouch U-200Insulin Degludec25$22,436
FarxigaDapagliflozin Propanediol16$15,574
TopamaxTopiramate12$14,205
Tresiba Flextouch U-100Insulin Degludec19$11,674
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$8,093
Spiriva HandihalerTiotropium Bromide13$6,261
ShingrixVaricella-Zoster Ge/As01b/Pf27$6,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$170$179,383122 claims
Boehringer IngelheimJardiance$69$98,391116 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$186$47,95481 claims
PfizerEliquis$473$47,28377 claims
Lilly USA, LLCMounjaro$255$33,88517 claims
AbbVieLinzess, Synthroid$567$33,21889 claims
Johnson & JohnsonXarelto$44$23,42943 claims
AstraZenecaFarxiga, Symbicort$151$20,69736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Sumrall

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →